Nataliya Uboha
Associate Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (38)
Summary of treatment de-escalation. Overview of dose de-escalation, number ( n ) of patients at each level, and number of patients experiencing a DLT at each dose level. bid, twice daily; D, day; IV, intravenously; PO, orally; qd, once a day.
Year:
2025
Elimusertib concentrations by toxicity. DLT occurrence and week 1 cumulative elimusertib based on day 2 AUC 0–12 hours by cisplatin dose. Open circles, individual patients; solid dash, geometric mean.
Year:
2025
Purpose: The ataxia telangiectasia and Rad3–related kinase inhibitor elimusertib synergizes with cisplatin preclinically. We evaluated the clinical feasibility of combining elimusertib with cisplatin. Patients and Methods: Patients with advanced solid tumors who had received 2 of prior cisplatin, and for whom cisplatin-based treatment was deemed appropriate, were enrolled according to a standard 3 + 3 design, starting elimusertib at 20 mg orally twice daily on days 2 and 9, with cisplatin 60 mg/m 2 intravenously on day 1 of a 21-day cycle. Primary objectives were the determination of the maximum tolerated dose and safety. Secondary objectives included the assessment of elimusertib pharmacokinetics and preliminary efficacy. Results: Fifteen patients were enrolled. Dose level −2 (elimusertib 20 mg once on day 2 and cisplatin 30 mg/m 2 on days 1 and 8) was deemed the maximum tolerated dose; dose-limiting toxicities (DLT) including creatinine increase, hypokalemia, febrile neutropenia, neutropenia, syncope, and thrombocytopenia, required dose de-escalation. Although the four patients with the highest elimusertib exposure all experienced hematologic DLTs within 1 week, they also received a higher day 1 cisplatin dose, precluding a definitive association of elimusertib exposure with DLT occurrence. Of 10 evaluable patients, one (10%) with clear-cell ovarian cancer had a partial response, whereas five (50%) had stable disease. Conclusions: Cisplatin combined with elimusertib was associated with hematologic toxicity requiring significant dose de-escalation. Elimusertib pharmacokinetics was consistent with prior studies. Only modest activity was observed. Further clinical evaluation of elimusertib plus cisplatin is not warranted. Significance: Preclinical data suggest synergy between cisplatin and the ataxia telangiectasia and Rad3–related inhibitor elimusertib, leading to this phase Ib trial in advanced solid tumors evaluating feasibility. The results do not support further examination of the combination due to DLTs observed in the absence of robust efficacy.
Year:
2025
A, PFS and ( B ) OS in the dose-expansion phase overall (ITT) population; ( C ) PFS and ( D ) OS in patients with low CD73 levels, and ( E ) PFS and ( F ) OS in patients with high CD73 levels. ITT, intent-to-treat; NC, not calculable.
Year:
2024
CONSORT diagram for the dose-expansion phase. “a” denotes arm A1: death ( n = 1); withdrawal by patient ( n = 8); other ( n = 4). Arm A3: death ( n = 1); withdrawal by patient ( n = 2); other ( n = 2). “b” denotes patients could be counted more than once in this category if they discontinued different chemotherapy options for different reasons. “c” denotes as permitted per study protocol, patients from arms A2 and A3 continued to receive immunotherapy off-study after the study closure on July 22, 2022, and patients from all arms continued to receive treatment per standard of care at their site. “d” denotes end of study status as defined in the protocol. “e” denotes “sponsor decision" and includes patients either still on treatment or in survival follow-up at the time of study closure. N , number of patients in each treatment group.
Year:
2024
Purpose: This multicenter phase II basket trial investigated the efficacy, safety, and pharmacokinetics of Debio 1347, an investigational, oral, highly selective, ATP-competitive, small molecule inhibitor of FGFR1–3, in patients with solid tumors harboring a functional FGFR1–3 fusion. Patients and Methods: Eligible adults had a previously treated locally advanced (unresectable) or metastatic biliary tract (cohort 1), urothelial (cohort 2), or another histologic cancer type (cohort 3). Debio 1347 was administered at 80 mg once daily, continuously, in 28-day cycles. The primary endpoint was the objective response rate. Secondary endpoints included duration of response, progression-free survival, overall survival, pharmacokinetics, and incidence of adverse events. Results: Between March 22, 2019, and January 8, 2020, 63 patients were enrolled and treated, 30 in cohort 1, 4 in cohort 2, and 29 in cohort 3. An unplanned preliminary statistical review showed that the efficacy of Debio 1347 was lower than predicted, and the trial was terminated. In total, 3 of 58 evaluable patients had partial responses, representing an objective response rate of 5%, with a further 26 (45%) having stable disease (≥6 weeks duration). Grade ≥3 treatment-related adverse events occurred in 22 (35%) of 63 patients, with the most common being hyperphosphatemia (13%) and stomatitis (5%). Two patients (3%) discontinued treatment due to adverse events. Conclusions: Debio 1347 had manageable toxicity; however, the efficacy in patients with tumors harboring FGFR fusions did not support further clinical evaluation in this setting. Our transcriptomic-based analysis characterized in detail the incidence and nature of FGFR fusions across solid tumors. See related commentary by Hage Chehade et al., p. 4549
Year:
2024
Baseline median variant allelic frequency (VAF) by KRAS status (A), exploratory OS and PFS stratified by baseline median VAF (B) and distribution of KRAS mutation status (C), VAF (D) and blood TMB (E) by arm
Year:
2024
Purpose: Pancreatic ductal adenocarcinoma upregulates CD73, potentially contributing to immune surveillance evasion. Combining oleclumab (CD73 inhibitor) and durvalumab with chemotherapy may identify an effective treatment option. Patients and Methods: We describe a multicenter phase Ib/II randomized clinical trial in patients with metastatic pancreatic ductal adenocarcinoma, untreated (cohort A) or previously received gemcitabine-based chemotherapy (cohort B; NCT03611556). During escalation, patients received oleclumab 1,500 or 3,000 mg, durvalumab 1,500 mg, and gemcitabine plus nab-paclitaxel (GnP; cohort A; n = 14) or modified FOLFOX (cohort B; n = 11). During expansion, cohort A patients ( n = 170) were randomized to GnP (arm A1), oleclumab [recommended phase II dose (RP2D)] with GnP (arm A2), or oleclumab (RP2D) with durvalumab plus GnP (arm A3). Primary objectives were safety (escalation) and objective response rate (expansion). Secondary objectives included progression-free survival (PFS) and overall survival (OS). Results: During escalation, 1/11 patients from cohort B (oleclumab 3,000 mg) experienced two dose-limiting toxicities. Oleclumab’s RP2D was 3,000 mg. During expansion, grade ≥3 treatment-related adverse events occurred in 67.7% (42/62) of patients in A1, 73.7% (28/38) in A2, and 77.1% (54/70) in A3. The objective response rate was 29.0%, 21.1%, and 32.9% in A1, A2, and A3, respectively (A1 vs. A3; P = 0.650). PFS [HR = 0.72; 95% confidence interval (CI), 0.47, 1.11] and OS (HR = 0.75; 95% CI, 0.50–1.13) were similar for A3 versus A1. Patients with high CD73 expression had improved PFS and OS in A3 versus A1, although this should be interpreted with caution. Conclusions: Although the safety profile was acceptable, this study did not meet its primary efficacy endpoint.
Year:
2024
Adagrasib, an irreversible, selective KRAS G12C inhibitor, may be an effective treatment in KRAS G12C -mutated colorectal cancer, particularly when combined with an anti-EGFR antibody. In this analysis of the KRYSTAL-1 trial, patients with previously treated KRAS G12C -mutated unresectable or metastatic colorectal cancer received adagrasib (600 mg twice daily) plus cetuximab. The primary endpoint was objective response rate (ORR) by blinded independent central review. Ninety-four patients received adagrasib plus cetuximab. With a median follow-up of 11.9 months, ORR was 34.0%, disease control rate was 85.1%, and median duration of response was 5.8 months (95% confidence interval [CI], 4.2–7.6). Median progression-free survival was 6.9 months (95% CI, 5.7–7.4) and median overall survival was 15.9 months (95% CI, 11.8–18.8). Treatment-related adverse events (TRAEs) occurred in all patients; grade 3–4 in 27.7% and no grade 5. No TRAEs led to adagrasib discontinuation. Exploratory analyses suggest circulating tumor DNA may identify features of response and acquired resistance. Significance: Adagrasib plus cetuximab demonstrates promising clinical activity and tolerable safety in heavily pretreated patients with unresectable or metastatic KRAS G12C -mutated colorectal cancer. These data support a potential new standard of care and highlight the significance of testing and identification of KRAS G12C mutations in patients with colorectal cancer. This article is featured in Selected Articles from This Issue, p. 897 See co-corresponding author Rona Yaeger discuss this research article, published simultaneously at the AACR Annual Meeting 2024: https://vimeo.com/932606282/f27a6e46f4
Year:
2024
Table S3. Efficacy summary per BICR with adagrasib plus cetuximab in previously treated patients with KRASG12C-mutated unresectable or metastatic CRC, overall, and in phase 1 and phase 2 cohorts.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (33)
Scott E. Kopetz
The University of Texas MD Anderson Cancer Center
Samuel Klempner
Associate Professor
Massachusetts General Hospital
Matthew Reilley
Assistant Professor
University of Virginia School of Medicine
Mariano Ponz-Sarvise
Universidad de Navarra
Paul Frankel
Research Professor
Beckman Research Institute, City of Hope
Wells Messersmith
Professor and Cancer Center Director
University of Colorado Cancer Center
Tanios Bekaii-Saab
Mayo Clinic
Arjun Mittra
Assistant Professor
The Ohio State University Comprehensive Cancer Center
Nancy Chan
Assistant Professor
NYU School of Medicine
Niharika Mettu
Duke University
Jan Beumer
Professor (PAR)
Johns Hopkins University
James Harding
Memorial Sloan Kettering Cancer Center
Ming Yin
Assistant Professor
The Ohio State University Wexner Medical Center
Yuanquan Yang
The Ohio State University Comprehensive Cancer Center
Lipika Goyal
Director of Gastrointestinal Oncology
Stanford University
Anne Noonan
Professor
The Ohio State University Comprehensive Cancer Center
Andrés Cervantes
Professor of Medicine
University of Valencia
Josep Tabernero
Associate Professor Faculty of Medicine
Universitat de Vic - Universitat Central de Catalunya
Philippe L. Bedard
University Health Network
Petros Grivas
University of Washington
Jin Won Kim
Professor
Seoul National University Hospital
Michael J. Overman
-
Razelle Kurzrock
-
Elena Garralda
Director
-
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
Ingo Mellinghoff
Department Chair
Memorial Sloan Kettering Cancer Center
Teresa Macarulla
Head of Gastrointestinal and Endocrine Tumor Unit
Hospital Clínic de Barcelona
Andrew Coveler
Fred Hutchinson Cancer Research Center
Nick Pavlakis
Professor
University of Sydney
Christos Fountzilas
Associate Professor
Roswell Park Comprehensive Cancer Center
Joshua K. Sabari
NYU Langone Health
Do-Youn Oh
Professor
Seoul National University Hospital
Mamta Parikh
Associate Professor
University of California Davis Comprehensive Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.